Zacks.com on MSN1d
Merck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck & Co., Inc. (NYSE ... The company also secured a $2 billion licensing deal with Chinese drugmaker Hansoh Pharma in December 2024 for an experimental weight loss pill. This strategic move ...
Merck (MRK) signed a licensing agreement with Chinese biotech company Hansoh Pharma (3692.HK) for its oral GLP-1 weigh-loss drug is valued as high as $2 billion. To watch more expert insights and ...
AbbVie entered the obesity space just a few months after Merck secured a licensing deal for an investigational oral weight-loss drug developed by China-based Hansoh Pharma. CHMP Endorses AbbVie ...
This coincided with another ADC deal potentially worth more than $1.5 billion from GSK, which licensed in an early stage ovarian and endometrial cancer drug, HS-20089, from Hansoh Pharma.
Zacks Investment Research on MSN4d
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin DrugAbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s ...
Atomwise is already working with some of the biggest names in pharma and medicine, including Merck & Co, Eli Lilly, and AbbVie. In 2019 they struck a major deal with China's Hansoh pharmaceuticals.
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback